Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

C. Smadja; R. Maldonado; S. Turcaud; M. C. Fournie-Zaluski; B. P. Roques

doi:10.1007/bf02245811

journal article Aug 01, 1995

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

C. Smadja R. Maldonado S. Turcaud M. C. Fournie-Zaluski B. P. Roques

Psychopharmacology Vol. 120 No. 4 pp. 400-408 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf02245811

Topics

No keywords indexed for this article. Browse by subject →

References

59

[1]

Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournie-Zaluski MC, Roques BP (1992) Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioidδ and dopamine D1 receptor stimulation. Eur J Pharmacol 216:157–166 10.1016/0014-2999(92)90356-9

[2]

Barber NS, Dourish CT, Hill DR (1989) The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39:307–328 10.1016/0304-3959(89)90045-6

[3]

Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M, Cesselin F (1991) Differential inhibitory/stimulatory modulation of spinal CCK release byμ andδ opioid agonists, and selective blockade ofμ-dependent inhibition byκ receptor stimulation. Neurosci Lett 124:204–207 10.1016/0304-3940(91)90094-a

[4]

Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, Cesselin F (1992) Opioid control of CCK-like material from the rat substantia nigra. J Neurochem 58:916–922 10.1111/j.1471-4159.1992.tb09344.x

[5]

Butcher SP, Varro A, Kelly JS, Dockray GJ (1989) In vivo studies on the enhancement of cholecystokinin release in the rat striatum. Brain Res 505:119–122 10.1016/0006-8993(89)90121-2

[6]

Calenco-Choukroun G, Daugé V, Gacel G, Roques BP (1991) Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by aμ-opioid receptor agonist. Eur J Pharmacol 209:267–271 10.1016/0014-2999(91)90181-o

[7]

Cesselin F, Bourgoin S, Artaud F, Hamon M (1984) Basic and regulatory mechanisms of in vitro release of Met-enkephalin from the dorsal zone of the rat spinal cord. J Neurochem 43:763–773 10.1111/j.1471-4159.1984.tb12798.x

[8]

Chang RLS, Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc Natl Acad Sci USA. 83:4923–4926 10.1073/pnas.83.13.4923

[9]

Chang RLS, Lotti VJ, Chen TB, Kunkel KA (1986) Characterization of the binding of [3H]-(±)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30:212–217

[10]

Charpentier B, Durieux C, Peleprat D, Dor A, Reibaud M, Blanchard JC, Roques BP (1988) Enzyme resistant CCK analogs with high affinities for central receptors. Peptides 9:835–841 10.1016/0196-9781(88)90130-1

[11]

Cooper SJ (1991) Interactions between endogenous opioids and dopamine: implications for reward and aversion. In: Willner P, Scheel-Kruger (eds) The mesolimbic dopaminergic system: from motivation to action. John Wiley,

[12]

Daugé V, Rossignol P, Roques BP (1988) Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective m and dopioid peptides or kelatorphan an inhibitor of enkephalin-degrading enzymes. Psychopharmacology 96:343–352 10.1007/bf00216060

[13]

De Felipe MC, Jiménez I, Castro A, Fuentes JA (1989) Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. Eur J Pharmacol 159:175–180 10.1016/0014-2999(89)90702-4

[14]

Derrien M, Noble F, Maldonado R, Roques BP (1993) CCK-A or CCK-B receptors activation lead to antinociception and to hyperalgesia respectively: evidence for an indirect interaction with the opioidergic system. Neurosci Lett 160:193–196 10.1016/0304-3940(93)90411-d

[15]

Derrien M, Durieux C, Roques BP (1994) Antidepressant-like effects of CCK-B antagonists in mice: antagonism by Naltrindole. Br J Pharmacol 111:956–960 10.1111/j.1476-5381.1994.tb14832.x

[16]

Ding XZ, Bayer BM (1993) Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res 625:139–144 10.1016/0006-8993(93)90146-e

[17]

Dockray GJ (1976) Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 264:568–570 10.1038/264568a0

[18]

Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990) The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 176:35–44 10.1016/0014-2999(90)90129-t

[19]

Durieux C, Ruiz-Gayo M, Pelaprat D, Roques BP (1986) Investigation on the metabolism of CCK8 analogues by rat brain slices. Neuropeptides 7:1–9 10.1016/0143-4179(86)90072-7

[20]

Durieux C, Ruiz-Gayo M, Couringer PJ, Bergeron F, Ducos B, Roques BP (1992) [3H]pBC 264, a suitable probe for studying cholecystokinin-β receptors binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol, 41:1089–1095

[21]

Faris PL, Komisaruk B, Waitkins LR, Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:1449–1451 10.1126/science.6294831

[22]

Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP (1992) Mixed-inhibitor prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35:2474–2481

[23]

Gall C, Lauterborn J, Burks D, Seroogy K (1987) Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 403:403–408 10.1016/0006-8993(87)90085-0

[24]

Gaudreau P, Lavigne GJ, Quirion R (1990) Cholecystokinin antagonists proglumide, Lorglumide and benzotrip, but not L-365,718 interact with brain opioid binding sites. Neuropeptides 16:51–55 10.1016/0143-4179(90)90029-x

[25]

Hill DR, Campbell NJ, Shaw TM, Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide antagonists. J Neurosci 7:2967–2976 10.1523/jneurosci.07-09-02967.1987

[26]

Hökfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285:476–478 10.1038/285476a0

[27]

Innis RB, Snyder SH (1980) Distinc cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77:6917–6921 10.1073/pnas.77.11.6917

[28]

Itoh S, Katsuura G, Maeda Y (1982) Caerulein and cholecystokinin suppressβ-endorphin-induced analgesia in the rat. Eur J Pharmacol 80:421–425 10.1016/0014-2999(82)90089-9

[29]

Kameyama T, Nagasaka M (1982) Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. Pharmacol Biochem Behav 17:59–63 10.1016/0091-3057(82)90263-5

[30]

Kameyama T, Nagasaka M, Yamada K (1985) Effects of antide-pressant drugs on a quickly learned conditioned suppression responses in mice. Neuropharmacology 24:59–63 10.1016/0028-3908(85)90133-9

[31]

Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF, Beinborn M (1992) Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 89:3605–3609 10.1073/pnas.89.8.3605

[32]

Ladurelle N, Keller G, Roques BP, Daugé V (1993) Effects of CCK8 and of a CCKB-selective agonist BC264 on extracellular dopamine content in the posterieur nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 628:254–262 10.1016/0006-8993(93)90962-m

[33]

Lanaud P, Popovici T, Normand E, Lemoine C, Bloch B, Roques BP (1989) Distribution of CCK mRNA in particular regions (hippocampus, periaqueducal grey and thalamus) of the rat by in situ hybridization. Neurosci Lett 104:38–42 10.1016/0304-3940(89)90325-x

[34]

Lavigne GJ, Millington WR, Mueller GP (1992) The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 21:119–129 10.1016/0143-4179(92)90522-x

[35]

Maldonado R, Daugé V, Feger J, Roques BP (1990) Chronic blockade of D2 but not D1 dompamine receptors facilitates behavioural responses to endogenous enkephalins protected by kelatorphan administered in the accumbens in rats. Neuropharmacology 29:215–223 10.1016/0028-3908(90)90004-b

[36]

Maldonado R, Derrien M, Noble F, Roques BP (1993) Association of the peptidase inhibitor and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport 4:947–950 10.1097/00001756-199307000-00028

[37]

Moran TH, Robilson MS, Goldrich MS, McHugh PR (1986) Two brain cholecystokinin receptors for behavioural actions. Brain Res 362:175–179 10.1016/0006-8993(86)91413-7

[38]

Nabeshima T, Katoh A, Kameyama T (1988) Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motility. J Pharmacol Exp Ther 244:303–309

[39]

Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) Inhibition of the enkephalinmetabolizing enzymes by the first systematically active mixed inhibitor prodrug RB101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261:181–190

[40]

Noble F, Derrien M, Roques BP (1993) Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109:1064–1070 10.1111/j.1476-5381.1993.tb13730.x

[41]

Noble F, Smadja C, Roques BP (1994) Role of endogenous cholecystokinin in the facilitation ofμ-mediated antinociception byδ-agonist. J Pharmacol Exp Ther 271:1127–1134

[42]

Pélaprat D, Broer Y, Studler JM, Peschanski M, Tassin JP, Glowinski J, Rostène W, Roques BP (1987) Autoradiography of CCK receptors in the rat brain using [3H]Boc[Nle28,31] CCK27–33 and [125I] Bolton-Hunter CCK8. Functional significance of subregional distributions. Neurochem Int 10:495–508 10.1016/0197-0186(87)90076-3

[43]

Pohl M, Benoliel JJ, Bourgoin S, Lombard MC, Mauborgne A, Taquet H, Carayon A, Besson JM, Cesselin F, Hamon M (1990) Regional distribution of calcitonin gene-related peptide-, substance P, cholecystokinin-, Met-enkephalin-, and dynorphin A (1–8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55:1122–1130 10.1111/j.1471-4159.1990.tb03114.x

[44]

Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptideδ-opioid receptor antagonist. Eur J Pharmacol 146:185–186 10.1016/0014-2999(88)90502-x

[45]

Roques BP, Daugé V, Gacel G, Fournié-Zaluski MC (1985) Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalin metabolism. Potential use in treatment of mental illness. In Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds) Biological psychiatry developments in psychiatry, vol 7. Elsevier, pp 287–289

[46]

Ruiz-Gayo M, Durieux C, Fournié-Zaluski MC, Roques BP (1992) Stimulation of ∂-opioid receptors binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 59:1805–1811 10.1111/j.1471-4159.1992.tb11013.x

[47]

Saito A, Sankaran H, Goldfine ID, Williams JA (1980) Cholecystokinin receptors in the brain: characterization and distribution. Science 208:1155–1156 10.1126/science.6246582

[48]

Sakamoto C, Williams JA, Godfine ID (1984) Brain CCK receptors are structurally distinct from pancreas CCK receptors. Biochem Biophys Res Commun 124:497–502 10.1016/0006-291x(84)91581-x

[49]

Tejedor-Real P, Micó JA, Maldonado R, Roques BP, Gibert-Rahola J (1993) Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalins degrading enzymes on a model of depression in the rat. Biol Psychiatry 34:100–107 10.1016/0006-3223(93)90262-c

[50]

Valverde O, Maldonado R, Fournié-Zaluski MC, Roques BP (1994) CCK-B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270:77–88

Showing 50 of 59 references

Metrics

38

Citations

59

References

Details

Published: Aug 01, 1995
Vol/Issue: 120(4)
Pages: 400-408
License: View

Authors

Laboratori de Neurofarmacologia Departament de Ciències Experimentals i de la Salut Universitat Pompeu Fabra Parc de Recerca Biomedica de Barcelona (PRBB) Spain; IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain

S

S. Turcaud

M

M. C. Fournie-Zaluski

B

B. P. Roques

Cite This Article

C. Smadja, R. Maldonado, S. Turcaud, et al. (1995). Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology, 120(4), 400-408. https://doi.org/10.1007/bf02245811

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

You May Also Like